Background: Dementia represents a potential challenge when thrombolysis is a treatment option. In this study, we assess the impact of dementia on the rate of intracerebral hemorrhage (ICH) and hospital mortality associated with acute ischemic stroke (AIS) in patients treated with thrombolysis.
mentia has been controversial. This is mainly due to the fact that most of the early randomized clinical trials excluded elderly subjects, especially those with poor baseline functional status. [8] [9] [10] [11] [12] We recently showed that thrombolysis was not associated with higher risk of mortality in the elderly population. 13 In this study, we sought to establish the impact of dementia on hospital mortality and intracerebral hemorrhage (ICH) rates associated with thrombolysis therapy for AIS.
METHODS Data cleansing and variables identification. We identified admissions for AIS from the Nationwide Inpatient Sample (NIS) database for the years of 2000 through 2007 by searching the International Classification of Disease, ninth Revision, Clinical Modification (ICD-9-CM). Because the NIS is a publicly available national database, we obtained an institutional review board exemption for waivers of informed consent and Health Insurance Portability and Accountability Act authorization from St. Louis University, School of Medicine. The inclusion and exclusion criteria as well as the ICD-9-CM codes were previously published. 13 In addition, missing observations on the death status (n ϭ 2,160, 0.2%) and observations on missing age (n ϭ 346) were eliminated from the total sample. Transfer between hospitals (n ϭ 38,285, 3.32%) and those with other diagnoses (n ϭ 15,6234, 13.5%) were excluded. The most common variable with missing information was race (24.8%), which was classified in 4 categories (white, black, Hispanic, and others).
In addition to in-hospital mortality, we identified common stroke-associated complications including intracranial hemorrhage, respiratory failure needing endotracheal intubation, systemic infection (or sepsis), and gastrointestinal hemorrhage. 13 A weighted composite comorbidity index score of 19 different chronic conditions was used; the index is ranked mild (chronic medical conditions without cancer), moderate (chronic medical conditions with cancer without metastasis), and severe (metastatic cancer and acquired immune deficiency syndrome). 14 This index was used to determine the impact of comorbidities on stroke outcomes.
Identifying the population with dementia. Clinical types of dementia were identified from the NIS dataset by the ICD-9-CM codes. These include Alzheimer disease (ICD-9-CM 331.0), Lewy body disease (331.82), frontotemporal dementia (331. 19) , Pick disease (331.11), senile (290.0) and presenile (290.10 -290.13), and vascular dementia (290.40 -290.43). Alcohol-induced dementia (291.2) was not included because chronic alcohol use is an independent risk factor for vascular disease and coagulopathy. 15
Statistical analysis. Student t test and Wilcoxon rank sum
test were used to compare the mean and median of continuous variables. 2 or Fisher exact tests were used to compare proportions between categories. For univariate analysis, we used Cochran-Mantel-Haenszel test. Among all patients with dementia, a multivariate stepwise logistic regression model was fitted to determine the independent association of significant variables (including the use of thrombolysis) for the outcome of inhospital mortality. Covariates used in the first model (with hospital mortality as an outcome) included the basic demographics gender, race, and socioeconomic status, hospital-associated complications (ICH, endotracheal intubation, gastrointestinal bleedings, and sepsis), and comorbidity index. For the outcome of ICH, the same covariates were used except hospital mortality. The significance level was set a priori at p Ͻ 0.001.
To identify the risk of thrombolysis in the group with dementia compared to matched patients without dementia, we performed simple random matching from the pool of the patients without dementia but treated with thrombolysis for AIS. The matched sample was abstracted from the NIS dataset for the same years included in this study. We employed a survey-select method which provides probability-based random sampling. The matched population was based on the basic demographics age, gender, and racial distribution in the treated population, in a ratio of 1:3; i.e., 3 treated patients without dementia were matched for each treated patient with dementia. Statistical significance was determined at p Ͻ 0.05. All statistical tests and sampling method were performed using SAS 9.2 (SAS Institute, Cary, NC). DISCUSSION Although prior studies have suggested increased risks of ICH and death associated with thrombolysis in the elderly population, 16, 17 these studies did not address the potential influence of dementia on certain outcomes, especially ICH. In this analysis, we found no significant differences in ICH (5.80%) or hospital mortality (17.4%) rates directly related to thrombolysis in the elderly patients with dementia. However, the presence of ICH remained a predictor of mortality in both patients with dementia and patients without dementia treated with thrombolysis. 18 The risk of ICH in our cohort was similar to those reported in large series, 19, 20 and slightly lower than those reported by the National Institute of Neurological Disorders and Stroke trial. 21 Similar to our results, recent time-tothrombolysis analysis of the major clinical trials showed a rate of ICH average 5.2% for 0 -360 minutes and the mortality 17.7% average for 0 -180 minutes. 22 Among the patients with dementia in the NIS dataset, those who received thrombolysis constituted only 0.58% of the total cohort, a much lower thrombolysis rate than the national sample. 13, 20, 23 In 2006, 1.28% of all ischemic strokes in elderly population received thrombolysis. 13 Possible explanations for this low rate include physicians' judgment of the risk of thrombolysis-related ICH in elderly patients with dementia. There is increasing evidence of a higher incidence of silent cerebral microbleed in the elderly population. 4 It is conceivable that thrombolysis may increase the risk of ICH in individuals with microbleeds. In addition, the older age profile of patients with ischemic stroke and the increased risk of hemorrhagic transformation contribute to the increased risk of thrombolysis-related ICH. 24, 25 In agreement with a prior report, 26 our results suggest a similar risk of ICH in elderly patients with dementia. Also important is physicians' belief of a lack or lower efficacy of thrombolysis in elderly patients with dementia. This issue remains debatable due to the lack of evidence to demonstrate the efficacy of thrombolysis in the elderly population. Third, end-of-life care is more likely to be determined in elderly patients and patients with dementia. In fact, less invasive therapy can be indirectly inferred in our cohort by the lower incidence of endotracheal intubation in the dementia (3.4%) compared to a no-dementia population (11.4%). This observation may reflect a conservative physician's attitude toward the elderly population or that elderly patients are more likely to have advanced directives such as do-not-resuscitate instructions to avoid invasive therapies including endotracheal intubation and thrombolysis.
RESULTS
The strength of our analysis includes the paucity of similar direct comparisons in the medical literature between patients with dementia and matched patients without dementia. The matching process may have reduced the effects of confounding variables as well as the variation in study results. 27 However, this study has limitations. First, our cohort lacks the baseline functional status especially for patients with dementia. We could not ascertain the baseline modified Rankin scale or the Barthel Index, 28 which are the common outcome measures in randomized trials. These would have been helpful to understand how physicians select patients for thrombolysis and could explain the low rate of thrombolysis in the sample with dementia. Thus, this study remains ob- servational and subject to selection bias. In addition, administrative large databases lack AIS-specific information such as time of onset, time to treatment, stroke severity, and the dose and type of the utilized thrombolytic agents. Finally, the NIS dataset lacks information on the standard 30-day outcomes as used in clinical trials. In this sample, thrombolysis did not increase the risk of ICH or death in elderly patients with dementia compared to controls without dementia. The results of this study cannot be utilized to provide high-level recommendations unless validated by a prospective study.
